Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

Roper, 2001, Excess mortality in a population with diabetes and the impact of material deprivation: longitudinal, population based study, BMJ, 322, 1389, 10.1136/bmj.322.7299.1389

Stamler, 1993, Diabetes, other risk factors, and 12-year cardiovascular mortality for men screened in the Multiple Risk Factor Interventional trial, Diabetes Care, 16, 434, 10.2337/diacare.16.2.434

Khaw, 2001, Glycated haemoglobin, diabetes, and mortality in men in Norfolk cohort of European Prospective Investigation of Cancer and Nutrition (EPIC-Norfolk), BMJ, 322, 15, 10.1136/bmj.322.7277.15

Haffner, 1998, Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction, N Engl J Med, 339, 229, 10.1056/NEJM199807233390404

2003, MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomized placebo-controlled trial, Lancet, 361, 2005, 10.1016/S0140-6736(03)13636-7

1998, Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34), Lancet, 352, 854, 10.1016/S0140-6736(98)07037-8

Yki-Jarvinen, 2004, Drug therapy: thiazolidinediones, N Engl J Med, 351, 1106, 10.1056/NEJMra041001

Pf˚tzner, 2005, Improvement of cardiovascular risk markers by pioglitazone is independent from glycemic control: results from the Pioneer study, J Am Coll Cardiol, 45, 1925, 10.1016/j.jacc.2005.03.041

Charbonnel, 2004, The prospective pioglitazone clinical trial in macrovascular events (PROactive): can pioglitazone reduce cardiovascular events in diabetes? Study design and baseline characteristics of 5238 patients, Diabetes Care, 27, 1647, 10.2337/diacare.27.7.1647

1999, A desktop guide to type 2 diabetes mellitus: European Diabetes Policy Group 1999, Diabet Med, 16, 716, 10.1046/j.1464-5491.1999.00166.x

Lan, 1989, Group sequential procedures: calendar versus information time, Stat Med, 8, 1191, 10.1002/sim.4780081003

Grambsch, 1994, Proportional hazards tests and diagnostics based on weighted residuals, Biometrica, 81, 515, 10.1093/biomet/81.3.515

Goldberg, 2005, A comparison of lipid and glycaemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia, Diabetes Care, 28, 1547, 10.2337/diacare.28.7.1547

Reaven, 1988, Banting lecture 1988: role of insulin resistance in human disease, Diabetes, 37, 1595, 10.2337/diab.37.12.1595

Charbonnel, 2005, Pioglitazone elicits long-term improvements in insulin sensitivity in patients with type 2 diabetes: comparisons with gliclazide-based regimens, Diabetologia, 48, 553, 10.1007/s00125-004-1651-9

2005, Tight glucose control lowers CVD by about 50 percent in diabetes, NIH News, 12

Feinglos, 1999, Therapy of type 2 diabetes, cardiovascular death, and the UGDP, Am Heart J, 138, S346, 10.1016/S0002-8703(99)70034-7

1998, Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33), Lancet, 352, 837, 10.1016/S0140-6736(98)07019-6